Expression of ADAM8 and its clinical values in diagnosis and prognosis of hepatocellular carcinoma
- 1 September 2012
- journal article
- research article
- Published by Springer Nature in Tumor Biology
- Vol. 33 (6) , 2167-2172
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeuticsExpert Review of Gastroenterology & Hepatology, 2009
- TACE versus TAE as therapy for hepatocellular carcinomaExpert Review of Anticancer Therapy, 2008
- Hepatocellular carcinoma: prevention, detection and treatment … in the real worldInternal Medicine Journal, 2007
- Non-Hodgkin lymphoma: an updateThe Lancet Oncology, 2004
- Ectodomain Shedding of the Neural Recognition Molecule CHL1 by the Metalloprotease-disintegrin ADAM8 Promotes Neurite Outgrowth and Suppresses Neuronal Cell DeathJournal of Biological Chemistry, 2004
- Catalytic Activity of ADAM8, ADAM15, and MDC-L (ADAM28) on Synthetic Peptide Substrates and in Ectodomain Cleavage of CD23Journal of Biological Chemistry, 2003
- Expression of ADAM‐9 mRNA and protein in human breast cancerInternational Journal of Cancer, 2003
- The ADAMs family of metalloproteases: multidomain proteins with multiple functionsGenes & Development, 2003
- The Metalloprotease Disintegrin ADAM8Journal of Biological Chemistry, 2002
- CD156 (Human ADAM8): Expression, Primary Amino Acid Sequence, and Gene LocationGenomics, 1997